Effects of topiramate on memory performance on the intracarotid amobarbital (Wada) test

Epilepsy and Behavior

Volumn 5, Issue 2, 2004, Pages 197-203

  Kipervasser, Svetlana ^a   Andelman, Fani ^a   Kramer, Uri ^a   Nagar, Sari ^a   Fried, Itzhak ^a,b   Neufeld, Miri Y ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epilepsy surgery; Memory; Topiramate; Wada test

Indexed keywords

AMOBARBITAL; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FEMALE; HEMISPHERE; HEMISPHERIC DOMINANCE; HUMAN; INTERMETHOD COMPARISON; LEFT HANDEDNESS; LONG TERM MEMORY; MALE; MENTAL PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; RIGHT HANDEDNESS; SCORING SYSTEM; SHORT TERM MEMORY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE EPILEPSY; WADA TEST;

EID: 1842636861     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2003.11.033     Document Type: Article

References (14)

1. Aldenkamp AP. Effects of antiepileptic drugs on cognition. Epilepsia 2001;42(Suppl 1):46-9.
2. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002;22:27-39.
3. Martin R, Kuzniecky R, Ho S, et al. Cognitive effect of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
4. Mecarelli O, Piacenti A, Pulitano P, et al. Clinical and electro-encephalographic effects of topiramate in patients with epilepsy and healthy volunteers. Clin Neuropharmacol 2001;24: 284-9.
5. Faught E, Wilder BJ, Ramsay RA, et al., for the Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
6. Privitera M, Fincham R, Penry J, et al., for the Topiramate YE Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-83.
7. Tatum 4th WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42:1134-40.
8. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003;60:1483-8.
9. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-78.
10. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636-41.
11. Kockelmann E, Elger CE, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 2003;54:171-8.
12. Mula M, Trimble MR, Thompson P, Sander JW. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003;60:1104-7.
13. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44:339-47.
14. McCabe PH, Eslinger PJ. Abnormal Wada and neuropsychological testing results due to topiramate therapy. Epilepsia 2000;41: 906-8.